Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by immature myeloblasts that proliferate without differentiating and interfere with normal hematopoiesis. After no advancements for decades, the last several years have brought numerous approvals including targeted therapies for biomarker-defined populations and venetoclax for newly diagnosed patients ineligible for chemotherapy. However, there remains a large unmet need for effective therapies in patients not eligible for allogeneic stem cell transplant and those with relapsed/refractory disease.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in AML to help guide strategic and tactical commercial development decisions for market participants.